Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Radiotherapy for Hodgkin Lymphoma: Reducing Toxicity While Maintaining Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of exercise on tumor physiology and metabolism

    Research output: Contribution to journalReviewResearchpeer-review

  1. A small change makes a big difference in Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) is currently the criterion standard of lymphoma imaging and recommended through all stages of Hodgkin lymphoma management. Accurate staging is important for risk stratification and initial choice of therapy and also for the planning of postchemoradiotherapy. 18-Fluoro-2-deoxy-D-glucose PET/CT frequently leads to upstaging and potentially a more intensive treatment. Visual-only assessment of staging and interim scans is being accompanied by quantitative and semiquantitative methods to measure metabolic tumor volume, total lesion glycolysis, and so on. It is still unclear if these methods significantly improve the value of FDG PET/CT by visual assessment only. Because of the good prognostic value of FDG PET/CT, a large number of studies have used interim FDG PET to tailor treatment to the individual patients, according to their early metabolic response rather than according to their pretreatment prognostic features. 18-Fluoro-2-deoxy-D-glucose PET/CT is standard of care for posttreatment response assessment but has no place in routine follow-up of Hodgkin lymphoma patients in remission.

Original languageEnglish
JournalCancer Journal
Volume24
Issue number5
Pages (from-to)215-222
Number of pages8
ISSN1528-9117
DOIs
Publication statusPublished - 25 Sep 2018

ID: 55736880